To hear about similar clinical trials, please enter your email below
Trial Title:
Clinical Study on Third-line Treatment of Advanced Duodenal Adenocarcinoma by Fuquinitinib Combined With Sindillimab
NCT ID:
NCT05810142
Condition:
Third-line Treatment
Dvanced Duodenal Adenocarcinoma
Furquinelone Combined With Sintilimab
Conditions: Official terms:
Adenocarcinoma
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Retrospective
Intervention:
Intervention type:
Drug
Intervention name:
furquimatinib and sintilimab
Description:
furquimatinib and sintilimab
Summary:
This research project is a single-center, retrospective clinical exploration study. It
aims to retrospectively analyze data from 20 patients with advanced duodenal
adenocarcinoma who received third-line treatment with furquinelone combined with
sintilimab, in order to determine the clinical efficacy and safety of this combination
therapy in advanced duodenal cancer.
Criteria for eligibility:
Study pop:
This study will include patients with advanced duodenal adenocarcinoma who received
third-line or above treatment with the combination of furquimatinib and sintilimab in
Renji Hospital from January 2019 to the present.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Patients must meet all of the following criteria to be eligible for inclusion:
Age between 18 and 80 years (inclusive); Imaging findings consistent with unresectable
local advanced, recurrent or metastatic duodenal adenocarcinoma; Histologically confirmed
unresectable local advanced, recurrent or metastatic duodenal adenocarcinoma; ECOG
performance status 0-2; At least one measurable or evaluable lesion according to RECIST
v1.1; Third-line or above treatment with the combination of sintilimab and furquimatinib.
Exclusion Criteria:
- Patients meeting any of the following criteria will be excluded:
Patients with incomplete clinical data or laboratory examination that affects statistical
analysis; Patients who have had other malignant tumors in the past 5 years; Patients who
have had arterial thrombotic diseases such as angina, myocardial infarction, and
transient ischemic attack in the past 6 months; Patients who have received other types of
anti-tumor or experimental treatment; Pregnant or lactating women; Patients with other
diseases or abnormal mental status that may affect the patient's treatment; Patients who
have received other types of immune therapy, anti-angiogenic drugs, or small-molecule
tyrosine kinase inhibitors.
Gender:
All
Minimum age:
18 Years
Maximum age:
75 Years
Healthy volunteers:
No
Start date:
July 1, 2023
Completion date:
December 31, 2026
Lead sponsor:
Agency:
RenJi Hospital
Agency class:
Other
Source:
RenJi Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05810142
